Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 595
- Registration Number
- NCT00002678
- Locations
- 🇨🇦
Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦William Osler Health Centre, Brampton, Ontario, Canada
🇨🇦Credit Valley Hospital, Mississauga, Ontario, Canada
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 1200
- Registration Number
- NCT00020566
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 175
- Registration Number
- NCT00030719
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium
🇳🇴Rikshospitalet University Hospital, Oslo, Norway
🇬🇧Birmingham Children's Hospital, Birmingham, England, United Kingdom
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 22
- Registration Number
- NCT00003727
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00030082
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00002594
- Locations
- 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Sylvester Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States
N99-02: Melphalan and Buthionine Sulfoximine
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 31
- Registration Number
- NCT00005835
- Locations
- 🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00003336
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027937
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT00003042
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.